ORYZON GENOMICS, S.A. from 14/06/2024 to 14/06/2024 14/06/2024 09:01 ORYZON GENOMICS, S.A. Other relevant information ORYZON presents preliminary data from the ongoing FRIDA trial with iadademstat plus gilteritinib in relapsed/refractory FLT3-mut acute myeloid leukemia at the European Hematology Association congress, EHA-2024. Register number: 29142